An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Press Release|Articles|April 4, 2025
Camber Pharmaceuticals Announces Addition of Sodium Sulfate, Potassium Sulfate, and Magnesian Sulfate Oral Solution
Listen
0:00 / 0:00
Key Takeaways
- Camber Pharmaceuticals has launched an osmotic laxative for colon cleansing before colonoscopy in adults.
- The solution contains sodium sulfate, potassium sulfate, and magnesium sulfate in specific dosages.
Advertisement
Camber Pharmaceuticals is excited to announce the addition of Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate Oral Solution.
Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adult patients.
Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution 17.5 g/3.13g/1.6g is available in a carton of (2) – 6 ounce bottles.
To find out more information on Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution, please visit:
Advertisement
Related to this article
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
Gut microbiome disruption from anti-anaerobic antibiotics weakens CAR T cell therapy, raising relapse and CRS/ICANS risk; stewardship and microbiome repair may improve cancer outcomes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
3
Ramantamig's 93.6% ORR and Outpatient CRS Control
4
After 180 Years, Multiple Myeloma Gets a Definition of Cure
5